Clinical Trial

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 4, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2020-07-29; most recent amendment 2025-11-03.
Status change: Not Yet Recruiting → Recruiting 2021-06-14
Trial Details
NCT Number NCT04496349
Lead Sponsor Ascentage Pharma Group Inc.
Conditions T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma
Enrollment 78 participants
Start Date 2021-07-12
Primary Completion 2026-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-04